Navigation Links
Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
Date:10/26/2007

MONTREAL, Oct. 26 /PRNewswire/ - The IND proposes a randomized Phase III pivotal clinical trial that will compare SP1049C plus Best Supportive Care (BSC) versus BSC alone for the treatment of patients with advanced adenocarcinoma of the esophagus, gastroesophageal junction and stomach who have failed adjuvant or 1st or 2nd line chemotherapy. Supratek Pharma is Sponsor of the IND and will direct the clinical development program. The Company will initiate the clinical trial after completion of a Special Protocol Assessment (SPA) which is currently ongoing.

Oleg Romar, President and Chief Executive Officer, said, "The IND clearance by the FDA is a significant and exciting milestone in the clinical development program of our lead product. SP1049C is first among our unique family of nanomedicines. We believe that our Biotransport(TM) polymers' ability to provide novel mechanisms of action to drugs that have gone through clinical development, greatly speeds the overall development time, reduces risk and builds on approved platforms".

"The IND brings Supratek Pharma one step closer to creating an effective treatment for patients with metastatic disease who have failed available therapies and for whom no approved salvage therapies exist. We are dedicated to the clinical development of our product pipeline and to our commitment to provide novel therapeutics against drug resistant and metastatic cancers", said Dr. Christopher E. Newman, Vice-President and Chief Medical Officer of Supratek Pharma.

About SP1049C

-------------

Supratek's lead anticancer drug candidate, SP1049C, is based on Biotransport(TM) polymer technology. This drug is a proprietary composition of poloxamers with one of the most potent cytotoxic drugs, doxorubicin. Doxorubicin is among the most widely utilized anticancer drugs but is limited in its clinical use by inherent or induced drug resistance. While SP1049C retains the fundamental therapeutic characteristics of doxo
'/>"/>

SOURCE Supratek Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Jharkhand Pharmacies Refuse To Sell Viagra
7. Setting up a new pharmaceutical industry in India
8. Medicis Pharmaceutical company enters pediatric market
9. Supply of Radiopharmaceuticals Hampered by Attacks
10. Pharma majors gear to supply anti-anthrax drug
11. Pharmacies in for a dose of bitter medicine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... Multi-purpose bilingual co...esigned for use by the business community to educa...y of subjects from Safety issues to Dinosuars to A... Saint Louis, MO (PRWEB) November 27, 200...lectronics or toys to keep them busy any hour of t...
(Date:11/26/2009)..., , PRINCETON, N.J., Nov. 27 /PRNewswire/ ...ll almost double over the next 25 years and annual...it $336 billion, up from $113 billion today, accor... Diabetes Care . The National Changing Diabetes... commissioned the analysis by a team from the Univ...
(Date:11/26/2009)...ns get a bigger thrill when on an emotional roller...26 (HealthDay News) -- Call it the fear factor mee...sts that spectators -- especially those who root f...tion if it,s a closely contested match and victory...n despair. , Chew on that this Thanksgiving wee...
(Date:11/26/2009)... Benton Communications anno...ss growth system for retailers struggling to make ...PRWEB) November 26, 2009 -- Flu fears is the type ...to the emergency room, according to Dr. David Bent... released business growth system – The Rfac...
(Date:11/25/2009)..., , EMERYVILLE, Calif., Nov. 25 /PRNewswir...aq: ONXX ) today announced that the company will ...Briefing ,, December 7, 2009 - 9:00 a.m. C...ll discuss data presentations surrounding carfilzo..., as featured at the 51st American Society of Hema...
Breaking Medicine News(10 mins):Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...e DNA scaffolding that supports and controls the e...ole in the alcohol withdrawal symptoms, particular...cs to stop using alcohol. , The finding is report..., DNA can undergo changes in function without any...
...April 2, 2008 Genoptix,Inc. (Nasdaq: GXDX ) toda...,of stockholders is scheduled to be held at 9:00am... in Carlsbad, CA., The Genoptix board of director... to vote at, the annual meeting., About Genoptix,...
...ian ICL(TM) Practice Building Program, Launches ...e Piece IOL, MONROVIA, Calif., April 2, 2008 STA...veloper, manufacturer and marketer of minimally,in...008 in Chicago, Illinois, it was announced here to...
... Chief Financial Officer -, - Full Year 2007 Resu... 2008 at 8:30 a.m. ET -, ...on (OTC Bulletin Board: PMQC, PMQCU, PMQCW), a lea...2008 to accept a,senior management position at ano...
...l 2, 2008 /Xinhua-PRNewswire-FirstCall/ -- China,B...BIU), a leading company,in the Nano-BioTech Indust...d product lines. The company presently produces na... attention with,the introduction of an Influenza p...
...rafted based on California Legislative Blue Ribbon... SACRAMENTO, Calif., April 2, 2008 Lawmakers,wil...ght bills to address,the issues related to the ris...:00am. The bills were inspired by a,report issued ...
Other Medicine News:Health News:Brain DNA 'remodeled' in alcoholism 2Health News:STAAR Surgical Plans Major Presence at ASCRS 2Health News:STAAR Surgical Plans Major Presence at ASCRS 3Health News:Chem Rx Corporation Announces Resignation of Chief Financial Officer 2Health News:Chem Rx Corporation Announces Resignation of Chief Financial Officer 3Health News:China Bionanometer Industries (CBIU) Describes their Current Production Capacity and Product Lines 2Health News:California Lawmakers Unveil Legislative Effort on Autism 2
(Date:11/25/2009)..., N.J., Nov. 25 Pharmass...ceutical company committed to discovering, develop... infections, reported financial results for the fi...0, 2009 Pharmasset held $58.4 million in cash, cas...Pipeline Update and 2009 Highlights ,, RG7128...
(Date:11/25/2009)...d STAFA, Switzerland, Nov. 25 Fro... of innovative hearing solutions, presented the se...ence, focusing on the special needs of the older p... experts in aging and audiology from around the wo... with older people with hearing loss for an opport...
(Date:11/25/2009)..., N.J., Nov. 25 The FDA granted tr...) tablets, a non-nucleoside reverse transcriptase ...cifically indicated for use in treatment-experienc...ith HIV-1 strains resistant to an NNRTI and other ...oval is based on 48-week data from two Phase 3 stu...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Is trash the solution to tackling climate change 3F 14282 1U M physicists create first atomic scale map of quantum dots 14279 1U M physicists create first atomic scale map of quantum dots 14279 2Obese Middle Aged Women Face Unhealthy Future 58481 1Obese Middle Aged Women Face Unhealthy Future 58481 2
...IRE)--Jul 11, 2007 - Neose Technologies,Inc. (Nas...ntations,were presented with its collaborative par... recombinant Factor VIIa at the XXIst,Congress of ...tasis,in Geneva, Switzerland. The data presented d... prolongs the active half-life of,rFVIIa. GlycoPEG...
...PRNewswire-FirstCall/ -- On Wednesday,July 11, 20....m.,Central European Time members of Cell Therapeu...ference call to discuss today,s,announcement of th...comparing CHOP-R to CPOP-R, in which pixantrone is...n first-line treatment of patients,with aggressive...
Other Medicine Technology:Neose Announces Presentation of Positive Preclinical Data on,GlycoPEGylated Factor VIIa at the XXI Congress of the International,Society on Thrombosis and Haemostasis 2Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2
Optima III Noninsulated Duck-Bill Grasp, without ratchet
Optima III Noninsulated Duck-Bill Grasper, with ratchet
5 mm shaft
Snap-In Snap-Out®-II Single Ring Handle with Finger Tang, insulated handle and shaft
Medicine Products: